Introduction {#s1}
============

Interventions for local advanced or metastatic solid tumors have evolved rapidly in recent years, among which immune checkpoint blockade therapy may be the most notable strategy ([@B66]; [@B39]; [@B65]). Indeed, immune checkpoint inhibitors (ICIs) targeting the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), a T-cell immune checkpoint receptor, or its ligand PD-L1 may be effective for various types of cancer and have brought significant improvements in clinical prognosis ([@B37]; [@B35]; [@B3]; [@B75]). However, these therapies benefit just a few of patients, with objective response rates (ORR) of about 15--25%, and even lower for pancreatic carcinoma, prostate cancer, ovarian carcinoma, triple negative breast cancer, and microsatellite stable colorectal cancer. It may be attributed to insufficient abundance of tumor neoantigens, tumor heterogeneity, and genetic variation among individuals. Besides, acquired tumor resistance of ICIs is also a challenge ([@B50]; [@B84]). Therefore, it is necessary to seek combination therapy strategy which can activate anti-tumor immunity and enhance treatment efficacy.

Researches have identified that abnormal tumor vasculature in the tumor microenvironment (TME) not only fuels tumor progression but also has a negative impact on the effectiveness of all types of anticancer therapies, especially immunotherapy. Elevated interstitial fluid pressure of the TME caused by the leaky nature of tumor vessels and dysfunctional lymphatic drainage, along with low expression level of cell adhesion molecules, such as vascular cell adhesion protein 1 (VCAM1) and intercellular adhesion molecule 1 (ICAM1), limits the entry of drugs and the trafficking of immune effector cells into tumors ([@B32]; [@B11]; [@B42]). Besides, angiogenic molecules presenting in the TME, such as vascular endothelial growth factor (VEGF), act as a mediator of tumor-associated immunosuppression. Firstly, VEGF directly prevent mobilization, trafficking, development, proliferation, and effector function of CD8-positive cytotoxic T lymphocytes (CTLs) ([@B62]; [@B82]). Secondly, VEGF could promote the recruitment and proliferation of immunosuppressive cells, including regulatory T (Treg) cells, myeloid-derived suppressor cells (MDSCs), and M2-like tumor-associated macrophages (TAMs) ([@B79]; [@B14]; [@B51]). Thirdly, maturation and antigen presentation of dendritic cells (DCs) might be suppressed by elevated VEGF ([@B29]; [@B28]). Thus, strategies inducing vascular normalization may restore immune cell functions and help to attenuate the immunosuppression of the TME, thereby improve the activity of immunotherapy. For example, sunitinib could increase T-cell and B-cell levels and decrease PD-1 expression in tumor-infiltrating T-cells as well as inhibit MDSCs and Treg cells into tumor ([@B34]; [@B82]). Bevacizumab and pazopanib could increase the infiltration or activity of CD8-positive and CD4-positive T-cells and enhance the maturation of DCs ([@B25]; [@B92]). However, recent studies have also shown that an adaptive immunosuppression caused by the up-regulation of PD-L1 in endothelial cells (ECs) and tumor cells after antiangiogenic therapies limits the activity of antiangiogenesis ([@B1]). It suggests that combination of antiangiogenesis and immune checkpoint blockade targeting PD-1/PD-L1 may be a good choice. More interestingly, bioinformatic analyses revealed that gene expression features related to vascular normalization correlate with immunostimulatory pathways, especially the activation and infiltration of T-cells. As a result, activating of CD4-positive T-cells by ICIs promoted the normalization of tumor vessels in return ([@B80]). Therefore, it demonstrates that vascular normalization and immune reprogramming have synergistic effect, which provides a basis for the rationality of the combination of ICIs and antiangiogenic agents.

Indeed, preclinical evidences have confirmed the efficacy of these combination regimens ([@B89]; [@B59]; [@B23]; [@B45]; [@B48]). For instance, in a mouse model of colon adenocarcinoma, treatment with axitinib led to an improved T-cell response, and it resulted in a synergistic therapeutic efficacy when combined with anti-PD-1 antibody ([@B48]). On the basis of preclinical data, these combination therapies have been tested in dozens of clinical trials, which reported promising outcomes in patients with metastatic melanoma, non-squamous non-small-cell lung carcinoma (NSCLC), and renal cell carcinoma (RCC). Among them, IMpower150 trial showed that atezolizumab plus chemotherapy plus bevacizumab significantly improved progression-free survival (PFS) and overall survival (OS) of patients with metastatic non-squamous NSCLC, regardless of mutational status and checkpoint expression of tumor ([@B72]). Similarly, in other two phase 3 trials on the first-line treatment of advanced or metastatic RCC, concomitant use of pembrolizumab and axitinib improved OS, PFS, and ORR over the standard of care ([@B73]), while combining avelumab with axitinib improved PFS and ORR ([@B60]).

However, despite the enhanced anti-tumor efficacy, the combination treatment is not without challenge, including the risk of added toxicity and increasing of immune-related adverse events (irAEs). As is well known, toxic effects associated with ICIs manifesting with autoimmune-like side-effects are commonly seen in the skin, gastrointestinal tract, pulmonary, hepatic, renal, nervous, hematologic, cardiovascular, and endocrine systems ([@B31]; [@B69]). Likewise, antiangiogenic monoclonal antibodies (mAbs) and small-molecule tyrosine kinase inhibitors (TKIs), the two main types of antiangiogenic agent, also have diverse adverse effects, mainly including hypertension, arterial thromboembolic events, proteinuria, bowel perforation, reversible posterior leukoencephalopathy syndrome, wound complications, and hemorrhage ([@B15]). At present, there is no systematic analysis of the toxicity of such a kind of combination. This review will focus on the severe treatment-related adverse events (trAEs) and irAEs of the concomitant use of ICIs and antiangiogenic agents.

Material and Methods {#s2}
====================

Search Strategy and Eligibility {#s2_1}
-------------------------------

The study was performed according to the "PRISMA" statement. Search was done on 31 May 2019. PubMed and Embase databases were searched for relevant literatures published in English using MeSH and keywords "nivolumab," "pembrolizumab," "atezolizumab," "avelumab," "ipilimumab," "durvalumab," "immune checkpoint inhibition" or "immune checkpoint inhibitors," combined with "bevacizumab," "ramucirumab," "anlotinib," "apatinib," "axitinib," "cabozantinib," "cediranib," "fruquintinib," "lenvatinib," "motesanib," "nintedanib," "pazopanib," "regorafenib," "sorafenib," "sunitinib," "vandetanib," "aflibercept," or "endostar." Studies included in this review were limited to clinical trial of any phase, retrospective study, or case report involving adult patients with solid tumors. Only original articles were included. Duplicates, conference abstracts or poster presentations, commentaries, reviews, and secondary reporting of clinical trials were excluded.

Studies involving concurrent treatment of ICIs and antiangiogenic agents were eligible. The study should properly describe the safety of the combination treatment. Studies not describing toxicity or the timing of antiangiogenic therapy in relation to ICIs were excluded. AEs should be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). If not, authors rated them accordingly. When more than one article reported the same trial, the most recent data was used. When patients in case report were from the same cohort of a clinical trial and were reported with the same AEs, the case report was excluded. All relevant articles underwent evaluation for eligibility by two independent authors (LG and XY) and then were verified by senior author (HZ and CY). Titles and abstracts were preliminary screened. Subsequently, full-text reading was used to check whether the study met inclusion or exclusion criteria.

Data Extraction {#s2_2}
---------------

Two authors (LG and XY) collected all data for included studies. Data was sought on authors, year of publication, study type, number of patients, as well as the type, dose, and treatment duration of ICIs and antiangiogenic agents. Tumor types and stages, follow-up time, toxicity, and management were also collected. Only grade 3--5 trAEs and irAEs were included for analysis.

Results {#s3}
=======

Included Studies and Overview {#s3_1}
-----------------------------

We initially identified a total of 1,883 references from database search. There were 348 papers excluded due to duplication, and the remaining 1,535 references were read with title and abstract. Subsequently, 104 relevant articles were further assessed for eligibility by full-text reviewing. Finally, 32 articles meeting the inclusion criteria were included into this systematic review ([**Figure 1**](#f1){ref-type="fig"}). Among them, there were 17 prospective studies (n = 2186), 5 retrospective studies (n = 104), and 10 case reports (n = 34), with the median number of patient as 70 per study. Studies of the combination of ICIs and anlotinib, fruquintinib, motesanib, nintedanib, regorafenib, vandetani, or aflibercept were not found. The concurrent use of ICIs and mAbs was reported in 15 studies ([**Table 1**](#T1){ref-type="table"}), while concurrent use of ICIs and TKIs was in 17 studies ([**Table 2**](#T2){ref-type="table"}).

![Search flow diagram.](fphar-10-01173-g001){#f1}

###### 

Included articles with concurrent ICIs and antiangiogenic mAbs.

  Authors             Study year   Study type       Patients (n)   Compounds and dosage                                                                                                                                                                                                                                                             Treatment timing                                  Primary tumor                                                                                   Follow-up (median time)   Toxicity (≥3)
  ------------------- ------------ ---------------- -------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------------- ---------------
  Wallin et al.       2016         Prospective      10             Bevacizumab 15 mg/kg i.v./3 w \* 1 cycle, and then atezolizumab 20 mg/kg i.v., bevacizumab 15 mg/kg i.v./3 w                                                                                                                                                                     Renal cell carcinoma (RCC)                        Advanced; metastatic                                                                            17.2 months               Y
  McDermott et al.    2018         Phase 2 trial    101            Atezolizumab 1,200 mg i.v., bevacizumab 15 mg/kg i.v./3 w                                                                                                                                                                                                                        RCC                                               Advanced; metastatic                                                                            20.7 months               Y
  Rini et al.         2019         Phase 3 trial    451            Atezolizumab 1,200 mg i.v., bevacizumab 15 mg/kg i.v./3 w                                                                                                                                                                                                                        RCC                                               Advanced; metastatic                                                                            15 months                 Y
  Reck et al.         2019         Phase 3 trial    394            Atezolizumab + bevacizumab + carboplatin + paclitaxel (atezolizumab 1,200 mg i.v., bevacizumab 15 mg/kg i.v./3 w)                                                                                                                                                                Non-squamous non-small-cell lung cancer (NSCLC)   Chemotherapy-naïve metastatic                                                                   19.6 months               Y
  Wu et al.           2017         Case report      1              Pembrolizumab + bevacizumab + cisplatin + gemcitabine (pembrolizumab 1 mg/kg i.v., bevacizumab 4 mg/kg i.v.)                                                                                                                                                                     Urothelial carcinoma (UC)                         Recurrent                                                                                       NR                        N
  Gadgeel et al.      2018         Phase 1 trial    24             Pembrolizumab + bevacizumab + carboplatin + paclitaxel (pembrolizumab 2(n = 11) or 10 mg/kg (n = 13) i.v., bevacizumab 15 mg/kg i.v./3 w \* 4 cycles, and then pembrolizumab + bevacizumab for 2 years)                                                                          Non-squamous NSCLC                                Stage IIIB/IV without EGFR mutations or ALK translocations                                      16.4 months               Y
  Blumenthal et al.   2016         Retrospective    10             Pembrolizumab 150 mg i.v., bevacizumab, dosage NR i.v.,/3 w                                                                                                                                                                                                                      Central nervous system (CNS) tumor                Recurrent                                                                                       NR                        N
  Kurz et al.         2018         Retrospective    28             Pembrolizumab 2 mg/kg i.v./3 w (n = 19), or nivolumab 3 mg/kg i.v./2 w (n = 12), bevacizumab 10 mg/kg i.v./2 w (n = 28)                                                                                                                                                          High-grade gliomas (HGGs)                         Recurrent                                                                                       NR                        N
  Mantica et al.      2018         Retrospective    43             Nivolumab 3 mg/kg i.v./2 w, bevacizumab, dosage NR                                                                                                                                                                                                                               HGGs                                              Advanced                                                                                        6.4 months                Y
  Kanda et al.        2016         Phase 1b trial   6              Nivolumab+paclitaxel+carboplatin+bevacizumab (nivolumab 10 mg/kg i.v., bevacizumab 15 mg/kg i.v./3 w \* 6 cycles, and then pembrolizumab + bevacizumab maintain)                                                                                                                 Non-squamous NSCLC                                Stage IIIB without indication for definitive thoracic radiotherapy; stage IV; recurrent         7.54 months               Y
  Normann et al.      2019         Prospective      5              Nivolumab 3 mg/kg i.v./2 w, bevacizumab dosage NR                                                                                                                                                                                                                                Platinum resistant ovarian cancer                 Recurrent                                                                                       30 weeks                  Y
  Shirali et al.      2016         Case report      1              Nivolumab 3 mg/kg i.v., bevacizumab 15 mg/kg i.v./3 w)                                                                                                                                                                                                                           NSCLC                                             Progression                                                                                     NR                        Y
  Hodi et al.         2014         Prospective      46             Ipilimumab 10 mg/kg i.v./3 w \*4 cycles, and then 10 mg/kg i.v./12 w + bevacizumab 7.5 mg/kg (cohort 1) or 15 mg/kg (cohort 2) i.v./3 w; ipilimumab 3 mg/kg i.v./3 w \*4 cycles, and then 3 mg/kg i.v./12 w + bevacizumab 7.5 mg/kg (cohort 3) or 15 mg/kg (cohort 4) i.v./3 w   Melanoma                                          Unresectable stage III; stage IV                                                                17.3 months               Y
  Carter et al.       2016         Case series      20             Ipilimumab 3 mg/kg i.v./3 w \*4 cycles, and then 3 mg/kg i.v./12 w, bevacizumab 10 mg/kg i.v./2 w                                                                                                                                                                                Glioblastoma                                      Grade IV disease or recurrent astrocytoma (grade II); progression or after first-line therapy   ≥12 weeks                 Y
  Arkenau et al.      2018         Phase 1 trial    26             Pembrolizumab 200 mg i.v. d1, ramucirumab 8 mg/kg i.v. d1, d8/3 w                                                                                                                                                                                                                Biliary tract cancer (BTC)                        Advanced; metastatic                                                                            15.7 months               Y

###### 

Included articles with concurrent ICIs and TKIs.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors           Study year   Study type       Patients (n)     Compounds and dosage                                                                                                                                         Primary tumor                                           Treatment timing                    Follow-up (median time)              Toxicity (≥3)
  ----------------- ------------ ---------------- ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------- ----------------------------------- ------------------------------------ ---------------
  Atkins et al.     2018         Phase 1b trial   52               Axitinib 3,5 or 7 mg p.o. bid continuously, (median dose: 8.8 mg/day), pembrolizumab 2 mg/kg i.v. d8/3 w                                                     RCC                                                     Advanced                            20.4 months                          Y

  Rini et al.       2019         Phase 3 trial    429              Axitinib 5 mg (2--10 mg) p.o. bid continuously, pembrolizumab 200 mg i.v./3 w                                                                                RCC                                                     Advanced, recurrent                 12.8 months                          Y

  Wilky et al.      2019         Phase 2 trial    33               Axitinib 5 mg (2--10 mg) p.o. bid continuously, pembrolizumab 200 mg i.v. d8/3 w up to 2y                                                                    Sarcomas, including alveolar soft-part sarcoma (ASPS)   Advanced; metastatic                14.7 months                          Y

  Choueiri et al.   2018         Phase 1b trial   55               Axitinib 5 mg p.o. bid, d1--7 (lead-in period), axitinib 5 mg p.o. bid continuously, avelumab 10 mg/kg i.v./2 w                                              RCC\                                                    Advanced                            52.1 weeks                           Y

  Motzer et al.     2019         Phase 3 trial    434              Axitinib 5 mg p.o. bid, avelumab 10 mg/kg i.v./2 w                                                                                                           RCC                                                     Advanced                            11.6 months                          Y

  Qiao et al.       2018         Case report      1                Pazopanib + pembrolizumab + RAK cells (pazopanib 200 mg p.o. qd for 2 days, 400 mg qd for 5 days, then 600 mg qd up to now, pembrolizumab 100 mg i.v./3 w)   Primary hepatic angiosarcoma (PHA)                      Advanced                            About 15 months                      N

  Amin et al.       2018         Phase 1 trial    20(P+N)33(S+N)   Pazopanib 800 mg p.o. qd, nivolumab 2 mg/kg i.v./3 w; sunitinib 50 mg p.o. qd/4 weeks on and 2 weeks off, nivolumab 2 mg/kg i.v./3 w                         RCC                                                     Advanced                            27.1 months (P+N); 50 months (S+N)   Y

  Paoluzzi et al.   2016         Retrospective    18               Pazopanib 400--800 mg p.o. qd, nivolumab 3 mg/kg i.v./2 w                                                                                                    Sarcomas                                                Relapsed metastatic; unresectable   ≥13 months                           Y

  Yu-Li Su et al.   2017         Case report      1                Pazopanib 400 mg p.o. qd continuingly, nivolumab 3 mg/kg i.v./2 w                                                                                            RCC                                                     Metastatic                          ≥4 months                            N

  Chen et al.       2017         Case report      1                Sorafenib 200 mg p.o. bid, pembrolizumab 2 mg/kg i.v. d1/3 w (4 w starting in cycle 3)                                                                       Hepatocellular carcinoma (HCC)                          End-stage                           NR                                   N

  Feng et al.       2017         Case series      6                Sorafenib 200 mg p.o. bid, nivolumab 3 mg/kg i.v. d1/3 w                                                                                                     HCC                                                     Advanced                            NR                                   N

  Mahmoud et al.    2016         Case report      1                Sunitinib 50 mg p.o. qd/4 weeks on and 2 weeks off, nivolumab NR                                                                                             RCC                                                     Metastatic                          ≥11 months                           N

  Lee et al.        2017         Phase 1 trial    14               Cediranib 20/30 mg p.o. qd, + durvalumab 10 mg/kg i.v./2 w; cediranib 20 mg p.o. qd/5 days on and 2 days off, + durvalumab 1,500 mg i.v./4 w                 Solid tumors                                            Recurrent; metastatic               NR                                   Y

  Zhao et al.       2019         Case report      1                Apatinib 500 mg p.o. qd, nivolumab 3 mg/kg i.v./2 w                                                                                                          Liver carcinosarcoma                                    Advanced                            About 15 months                      Y

  Makker et al.     2019         Phase 2 trial    53               Lenvatinib 20 mg p.o. bid, pembrolizumab 200 mg i.v./3 w                                                                                                     Endometrial cancer                                      Metastatic                          13.3 months                          Y

  Iyer et al.       2018         Retrospective    12               Lenvatinib 20 mg p.o. bid, pembrolizumab 200 mg i.v./3 w                                                                                                     Anaplastic thyroid carcinoma (ATC)                      Progression                         13.74 months (8.14 + 5.6)            Y

  Bhat et al.       2019         Case report      1                Cabozantinib, nivolumab, dosage NR                                                                                                                           RCC                                                     Metastatic                          NR                                   N
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The reported treatment-related toxicities of included studies were listed in [**Table 3**](#T3){ref-type="table"}. When ICIs combined with mAbs (n = 1166), severe toxicity reported as grade 3/4 and grade 5 AEs was observed in 501 (43%) and 18 (1.5%) patients, respectively ([**Figures 2A, B**](#f2){ref-type="fig"}), while for ICIs plus TKIs (n = 1158), grade 3/4 and grade 5 AEs were in 687 (59.3%) and 9 (0.8%) patients, respectively ([**Figures 2A, C**](#f2){ref-type="fig"}). Overall, the total incidence of severe trAEs associated with ICIs plus mAbs was lower than that of ICIs plus TKIs ([**Figures 2B, C**](#f2){ref-type="fig"}).

###### 

Treatment-related toxicity as observed within the included articles.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antiangiogenic agents   ICIs                         Study               Median treatment duration           Patients (n)   Grade 3 (n) trAE/irAE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Grade 4 (n) trAE/irAE                                                                                                                                                                                                                                                                                                                                             Grade 5 (n) trAE/irAE              Total toxicity (≥3)                                                                                                                                   Management
  ----------------------- ---------------------------- ------------------- ----------------------------------- -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bevacizumab                                                                                                  1,140          494                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    18                                                                                                                                                                                                                                                                                                                                                                512                                                                                                                                                                                      

                          Ipilimumab                   Hodi et al.         NR                                  46             ALT (n = 2), AST (n = 2), abdomen pain (n = 2), adrenal insufficiency (n = 2), allergic reaction (n = 1), colitis (n = 2), endocrine-other (n = 1), fatigue (n = 1), head or headache (n = 1), hemorrhage-other (n = 1), hepatic-other (n = 1), hypertension (n = 4), hyponatremia (n = 2), lipase (n = 2), lymphopenia (n = 1), mucostomatitis by exam, oral cavity (n = 1), rash or desquamation (n = 2), thrombosis or thrombus or embolism (n = 1), vascular-other (n = 1). Among them, 5 trAEs were observed in cohort 1, 8 were in cohort 2, 6 were in cohort 3, and 10 in cohort 4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Hepatic-other (n = 1), proteinuria (n = 2)\                                                                                                                                                                                                                                                                                                                       0                                  13                                                                                                                                                    NR
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     All above were observed in cohort 2\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Number of patient was 13 (grade 3/4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                                       Carter et al.       65% patients complete four cycles   20             Diarrhea (n = 1), abscess formation (dental, uterine, diverticular) (n = 3), intracerebral bleed (n = 1), pulmonary embolism (n = 2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   0                                                                                                                                                                                                                                                                                                                                                                 0                                  7                                                                                                                                                     Three abscess were managed surgically; corticosteroids (diarrhea), dosage NR; NO discontinued treatment.

                          Pembrolizumab                Gadgeel et al.      Pemb: 10 doses (30 weeks)           24             Thrombocytopenia (n = 1), neutrophil count decreased (n = 1), white blood cell count decreased (n = 2)/colitis (n = 1), pneumonitis (n = 1), pancreatitis (n = 1). Grade 3 trAEs occurred in 10 (42%) and 10 (40%) patients with or without bevacizumab, respectively. Grade 3 irAEs and infusion reactions occurred in 5 (20.8%) and 1 (4%) patients with or without bevacizumab, respectively.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0                                                                                                                                                                                                                                                                                                                                                                 0                                  10                                                                                                                                                    Discontinuation: pembrolizumab 2 mg/kg group (n = 2, 18%); 10 mg/kg group (n = 3, 23%)

                                                       Blumenthal et al.   Pemb: 3 doses (9 weeks)             10             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NR                                                                                                                                                                                                                                                                                                                                                                NR                                 0                                                                                                                                                     Steroids weaned off or minimal 2 mg/d

                                                       Wu et al.           11 cycle (about 7.7 months)         1              NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NR                                                                                                                                                                                                                                                                                                                                                                NR                                 0                                                                                                                                                     A mild immune-related skin was resolved completely with anti-histamines.

                          Pembrolizumab or nivolumab   Kurz et al.         NR                                  28             0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      0                                                                                                                                                                                                                                                                                                                                                                 0                                  0                                                                                                                                                     On steroids when pembrolizumab initiated: n  = 17 (55%), dosage NR\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Discontinuation: n = 1 (3%)

                          Nivolumab                    Mantica et al.      8 cycle (about 16 weeks)            43             Pneumonitis (n = 1) / irAEs (including colitis and pneumonitis): n = 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Pneumonitis (n = 2), colitis (n = 1)                                                                                                                                                                                                                                                                                                                              0                                  4                                                                                                                                                     Discontinuation: n = 4 (8%)

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                       Kanda et al.        NR                                  6              White blood cell count decreased (n = 3), neutrophil count decreased (n = 6), lymphocyte count decreased (n = 1), anemia (n = 1), platelet count decreased (n = 2), febrile neutropenia (n = 1)/select adverse events (those with a potential immunologic cause) (n = 0); number of patient was 6.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     0                                                                                                                                                                                                                                                                                                                                                                 6                                  No discontinuation.\                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NR                                                                                                                                                    

                                                       Normann et al.      Bev: 16 weeks\                      5              Hepatitis (n = 1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     0                                                                                                                                                                                                                                                                                                                                                                 Intestinal perforation (n = 1);\   3                                                                                                                                                     Grade 2 events continued treatment after administration of steroids (dosage NR)\
                                                                           Nivo: 12 weeks                                     There was a tendency toward increased toxicity when using concomitant bevacizumab \[2 (40%) of 5 vs. 1 (11%) of 9\].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Believed to cause by bevacizumab                                                                                                                                                         Discontinuation because of nivolumab: n = 2 (14%)

                                                       Shirali, et al.     10 months                           1              Acute interstitial nephritis (n = 1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   NR                                                                                                                                                                                                                                                                                                                                                                NR                                 1                                                                                                                                                     Hospitalization: methylprednisolone 125 mg i.v. for 3 days, followed by prednisone 60 mg/d p.o., which was tapered over the next month.

                          Atezolizumab                 Wallin et al.       Atez: 15.9 months                   10             Hypertension (n = 3), acute respiratory failure (n = 1), hypercalcemia (n = 1), abdominal pain (n = 1)/n = 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0                                                                                                                                                                                                                                                                                                                                                                 6                                  NR                                                                                                                                                    

                                                       McDermott et al.    Bev: 10.3 months\                   101            Fatigue (n = 2), diarrhea (n = 4), nausea (n = 1), palmar--plantar erythrodysaesthesia syndrome (PPE) (n = 2), decreased appetite (n = 2), stomatitis (n = 2), headache (n = 1), arthralgia (n = 1), proteinuria (n = 8)/elevated liver enzymes or hepatitis (n = 4).\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Intracrinal hemorrhage (n = 1)                                                                                                                                                                                                                                                                                                                                    41                                 Discontinuation: n = 9 (9%)\                                                                                                                          
                                                                           Atezb: 11.8 months                                 TrAEs significantly increased with addition of bevacizumab (40 vs. 17%), but frequencies of irAEs were similar (5 \[5%\] of 101 vs. 3\[3%\] of 103).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Dose modification or interruption: n = 61 (60%)                                                                                                       

                                                       Rini et al.         12 months                           451            Hypertension (n = 63), fatigue (n = 6), hypothyroidism (n = 1), diarrhea (n = 7), proteinuria (n = 15), rush (n = 3), arthralgia (n = 10), decreased appetite (n = 2), nausea (n = 1), stomatitis (n = 2), mucosal inflammation (n = 1), anemia (n = 1), thrombocytopenia (n = 3), neutropenia (n = 2)/rush (n = 3), hypothyroidism (n = 1), hyperthyroidism (n = 1), LFT abnormalities (n = 13), colitis (n = 4), pneumonitis (n = 4).\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Cerebral infarction (n = 1, with known hypercholesterolaemia), intracranial hemorrhage (n = 1, following a fall), adrenal insufficiency (n = 1, with a history of coronary artery disease and myocardial infarction), multiple organ dysfunction syndrome (n = 1, following a post-radiation ulcer with cecum perforation), sepsis (n = 1, following pneumonia)   187                                Discontinuation:treatment regimen n = 24 (5%), any treatment component n = 53 (12%)\                                                                  
                                                                                                                              Frequency of trAEs was lower than that of sunitinib \[182 (40%) of 451 vs. 240 (54%) of 446\].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Systemic corticosteroids: n = 74 (16%)\                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          High-dose systemic corticosteroids (prednisone ≥40 mg/d or equivalent): n = 42 (9%)                                                                   

                                                       Reck et al.         Bev: 6.7 months\                    394            Peripheral neuropathy (n = 11), nausea (n = 15), fatigue (n = 13), anemia (n = 24), decreased appetite (n = 10), diarrhea (n = 11), neutropenia (n = 54), hypertension (n = 25), arthralgia (n = 3), asthenia (n = 5), epistaxis (n = 4), vomiting (n = 6), decreased platelet count (n = 20), myalgia (n = 2), thrombocytopenia (n = 16), proteinuria (n = 10), decreased neutrophil count (n = 34), rush (n = 5), stomatitis (n = 4), febrile neutropenia (n = 33), decreased white blood cell count (n = 13), decreased weight (n = 4), alt increased (n = 4), dehydration (n = 8), AST increased (n = 4), leukopenia (n = 7), hypokalemia (n = 7), pulmonary embolism (n = 7), hyponatremia (n = 8), pneumonia (n = 7), pneumonitis (n = 4), colitis (n = 5), transaminases increased (n = 4), cerebrovascular accident (n = 1), sepsis (n = 1)/rash (n = 9), hepatitis (laboratory abnormalities) (n = 16), hypothyroidism (n = 1), hyperthyroidism (n = 1), pneumonitis (n = 6), colitis (n = 5), hepatitis (diagnosis) (n = 4), adrenal insufficiency (n = 1), pancreatitis (n = 2), hypophysitis (n = 1), nephritis (n = 1), ocular inflammatory toxicity (n = 1), myositis (n = 1), encephalitis (n = 1), meningoencephalitis (n = 1); information was from an article reporting the same trial (Socinski et al., 2018). TrAEs elevated with addition of bevacizumab or atezolizumab (56.7 vs. 43%, 56.7 vs. 48.5%). But the addition of bevacizumab did not significantly increased irAEs (12.5 vs. 9.5%).   Febrile neutropenia (n = 3), hemoptysis (n = 3), pulmonary hemorrhage (n = 2), cerebrovascular accident (n = 1), aortic dissection (n = 1), intestinal obstruction (n = 1).\                                                                                                                                                                                      234                                Discontinuation or interruption\                                                                                                                      
                                                                           Atez: 8.2 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Information was from an article reporting the same trial (Socinski et al., 2018).\                                                                                                                                                                                                                                                                                                                   No dose reduction for atezolizumab or bevacizumab\                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Treatment-related death elevated with addition of bevacizumab (2.8 vs. 1%), but the addition of atezolizumab did not significantly increased it (2.8 vs. 2.3%).                                                                                                                                                                                                                                      Steroids, dosage NR                                                                                                                                   

  Ramucirumab                                                                                                  26             7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      0                                                                                                                                                                                                                                                                                                                                                                 7                                                                                                                                                                                        

                          Pembrolizumab                Arkenau et al.      Ramu: 9 weeks\                      26             Hypertension (n = 5), alanine aminotransferase increased (n = 1), aspartate aminotransferase increased (n = 1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         0                                                                                                                                                                                                                                                                                                                                                                 0                                  7                                                                                                                                                     Discontinuation: n = 1 (3.8%)
                                                                           Pemb: 9.3 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Apatinib                                                                                                     1              1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      0                                                                                                                                                                                                                                                                                                                                                                 1                                                                                                                                                                                        

                          Nivolumab                    Zhao et al.         About 7 months                      1              Elevated aminotransferases (n = 1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NR                                                                                                                                                                                                                                                                                                                                                                NR                                 1                                                                                                                                                     Discontinued and received liver-protecting drugs with magnesium isoglycyrrhizinate injection and transmetil for 3 weeks.

  Axitinib                                                                                                     1003           594                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    8                                                                                                                                                                                                                                                                                                                                                                 602                                                                                                                                                                                      

                          Pembrolizumab                Atkins et al.       14.5 months                         52             Fatigue (n = 5), diarrhea (n = 5), hypertension (n = 12), increased alanine aminotransferase concentration (n = 4), decreased appetite (n = 1), nausea (n = 1), palmar--plantar erythrodysaesthesia (n = 2), increased aspartate aminotransferase concentration (n = 2), weight decreased (n = 2), proteinuria (n = 1), oral pain (n = 1), headache (n = 2), vomiting (n = 1), dizziness (n = 1)/diarrhea (n = 4), increased alanine aminotransferase concentration (n = 2), increased aspartate aminotransferase concentration (n = 2), fatigue (n = 2), weight decreased (n = 1), colitis (n = 1), lymphocyte count decreased (n = 1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Hyperuricemia (n = 1)/hyperuricemia (n = 1)                                                                                                                                                                                                                                                                                                                       0                                  34                                                                                                                                                    Axitinib dose modification + symptomatic treatment: axitinib starting dose: 5 mg bid; dose level-1: 3 mg bid; dose level-2: 2 mg bid; permanently discontinued.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                For pembrolizumab: hold treatment until toxicity was \<grade 2; discontinue if toxicity does not resolves within 12 weeks of last dose or inability to reduce corticosteroids to 10 mg or less of prednisone or equivalent per day within 12 weeks; permanently discontinue

                                                       Rini et al.         Pemb+axi: 8.3 months\               429            Diarrhea (n = 31), hypertension (n = 91), hypothyroidism (n = 1), fatigue (n = 10), palmar--plantar erythrodysesthesia (n = 22), alanine aminotransferase increased (n = 52), dysphonia (n = 1). Aspartate aminotransferase increased (n = 29), decreased appetite (n = 9), nausea (n = 2), proteinuria (n = 11), stomatitis (n = 3), mucosal inflammation (n = 4), pruritus (n = 1), arthralgia (n = 3), hyperthyroidism (n = 4), asthenia (n = 6), rash (n = 1), dysgeusia (n = 1), vomiting (n = 1), platelet count decrease (n = 1), anemia (n = 1), neutrophil (n = 1), neutrophil count decreased (n = 1)/hypothyroidism (n = 1), hyperthyroidism (n = 5), adrenal insufficiency (n = 3), hepatitis (n = 10, pneumonitis (n = 2), thyroiditis (n = 1), colitis (n = 8), severe skin reactions (n = 5), infusion reactions (n = 1), nephritis (n = 1), hypophysitis (n = 4), myasthenic syndrome (n = 2), myositis (n = 1), myocarditis (n = 2), pancreatitis (n = 2), type 1 diabetes mellitus (n = 1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Myasthenia gravis (n = 1), myocarditis (n = 1), necrotizing fasciitis (n = 1), pneumonitis (n = 1)/myasthenia gravis (n = 1), myocarditis (n = 1), pneumonitis (n = 1)\                                                                                                                                                                                           270                                Interruption: n = 267 (62.2%)\                                                                                                                        
                                                                           Pemb: 9.2 months\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Incidence of treatment-related death was lower than that of sunitinib \[4(0.9%) vs. 7 (1.6%)\].                                                                                                                                                                                                                                                                                                      Discontinuation of both pembrolizumab and axitinib: n = 35 (8.2%)\                                                                                    
                                                                           Axi: 9.6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Dose reduction of axitinib: n = 86 (20%)\                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Steroids, dosage NR                                                                                                                                   

                                                       Wilky et al.        NR                                  33             Oral mucositis (n = 1), nausea or vomiting (n = 2), diarrhea (n = 1), abdominal pain or dyspepsia (n = 1), hypertension (n = 5), hemoptysis (n = 1), pneumothorax (n = 1), seizures (n = 2)/hyperglycemia (n = 1), autoimmune hepatitis (n = 1), autoimmune colitis (n = 1), autoimmune arthritis (n = 2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Elevated ALT, AST, or AP (n = 1), hypertriglyceridemia or hyperlipidemia (n = 1)                                                                                                                                                                                                                                                                                  0                                  16                                                                                                                                                    Axitinib dose modification + symptomatic treatment: axitinib starting dose: 5 mg bid. If grade 2 or greater toxicity, dose level-1: 4 mg bid; dose level-2: 3 mg bid; dose level-3: 2 mg bid; permanently discontinued.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Steroids and discontinuation of study treatment: n = 3 (9%).\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                One patient with autoimmune arthritis was also given methotrexate and hydroxychloroquine.

                          Avelumab                     Choueiri et al.     Axi: 66.6 weeks\                    55             Diarrhea (n = 2), hypertension (n = 16), fatigue (n = 2), PPE syndrome (n = 4), ALT increased (n = 4), rush (n = 1), AST increased (n = 1), amylase increased (n = 3), decreased appetite (n = 1), mucosal inflammation (n = 1), infusion-related reaction (n = 1), lipase increased (n = 1), nausea (n = 1), arthralgia (n = 1), weight decreased (n = 1), proteinuria (n = 2), hypophosphatemia (n = 2), blood triglycerides increased (n = 1), dehydration (n = 1), pain in extremity (n = 1), drug eruption (n = 1), dyslipidemia (n = 1), urticaria (n = 1), venous thrombosis (n = 1)/rash (n = 2), hepatitis (n = 2), colitis (n = 1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Amylase increased (n = 1), lipase increased (n = 3), hematoma (n = 1), pulmonary embolism (n = 1)                                                                                                                                                                                                                                                                 Myocarditis (n = 1)                33                                                                                                                                                    Dose interruption of avelumab: n = 1 (1.8%)\
                                                                           Ave: 66.0 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Discontinuation of avelumab: n = 7 (13%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Discontinuation of axitinib: n = 4 (7%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Dose reductions of axitinib: n = 28 (51%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Steroids, dosage NR

                                                       Motzer et al.       Axi: 9.0 months\                    434            Diarrhea (n = 22), hypertension (n = 106), fatigue (n = 13), PPE syndrome (n = 25), dysphonia (n = 2), nausea (n = 3), hypothyroidism (n = 1), stomatitis (n = 8), decreased appetite (n = 7), chills (n = 1), mucosal inflammation (n = 5), alanine aminotransferase increased (n = 21), rash (n = 2), dyspnea (n = 6), arthralgia (n = 1), infusion-related reaction (n = 7), aspartate aminotransferase increased (n = 12), weight decreased (n = 7), vomiting (n = 1), asthenia (n = 5), thrombocytopenia (n = 1), anemia (n = 1), neutropenia (n = 1)/n = 39, events NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Sudden death (n = 1), myocarditis (n = 1), necrotizing pancreatitis (n = 1)/n = 0                                                                                                                                                                                                                                                                                 249                                Discontinuation of both avelumab and axitinib: n = 33 (7.6%)\                                                                                         
                                                                           Ave: 8.6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Dose reduction of axitinib: n = 183 (42.2%)\                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          High-dose glucocorticoids (≥40 mg total daily dose of prednisone or equivalent): n = 48 (11.1%)                                                       

  Cabozantinib                                                                                                 1              0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        0                                  0                                                                                                                                                     

                          Nivolumab                    Bhat et al.         NR                                  1              NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NR                                                                                                                                                                                                                                                                                                                                                                0                                  0                                                                                                                                                     NR

  Cediranib                                                                                                    14             7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        0                                  7                                                                                                                                                     

                          Durvalumab                   Lee et al.          \>15 months                         14             \(1\) Once-daily cediranib: lymphopenia (n = 1), anemia (n = 2), nausea (n = 1), diarrhea (n = 3), colitis (n = 1), fatigue (n = 1), headache (n = 1), hypertension (n = 3), pulmonary thromboembolism (n = 1), pulmonary hypertension (n = 1). Number of patient was 7; (2) intermittent cediranib:fatigue (n = 1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \(1\) Once-daily cediranib: lymphopenia (n = 1), pulmonary thromboembolism (n = 1); (2) intermittent cediranib: hypertension (n = 1)                                                                                                                                                                                                                              NR                                 7                                                                                                                                                     Discontinued or dose reduced of daily cediranib: n = 7 (87.5%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Systemic corticosteroids, dosage NR

  Lenvatinib                                                                                                   58             40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1                                                                                                                                                                                                                                                                                                                                                                 41                                                                                                                                                                                       

                          Pembrolizumab                Makker et al.       NR                                  53             Fatigue (n = 3), diarrhea (n = 4), palmar--plantar erythrodysesthesia syndrome (n = 3), hypertension (n = 18), proteinuria (n = 1), oral pain (n = 1), dehydration (n = 1), increased aspartate aminotransferase (n = 1), anemia (n = 1), hyponatremia (n = 2), increased lipase (n = 1), increased alanine aminotransferase (n = 1), prolonged electrocardiogram qt interval (n = 1), hypocalcaemia (n = 1), acute kidney injury (n = 2), pulmonary embolism (n = 2), syncope (n = 2), adrenal insufficiency (n = 1), cardiac failure (n = 1), colitis (n = 1), dysarthria (n = 1), hypertensive encephalopathy (n = 1), ischemic colitis (n = 1), neutropenia, pancreatitis (n = 1), retinal vein occlusion (n = 1), small intestinal obstruction (n = 1), upper abdominal pain (n = 1)/n = 30, irAEs (including skin, endocrine, gastrointestinal, pulmonary, hepatic, and renal adverse events), but grade NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      0                                                                                                                                                                                                                                                                                                                                                                 Intracranial hemorrhage (n = 1)    37                                                                                                                                                    Discontinued: n = 5 (9%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                High-dose glucocorticoids (≥40 mg/d of prednisone or equivalent): n = 3 (10%)

                                                       Iyer et al.         5.6 months                          5              Fatigue (n = 1), hypokalemia (n = 1), weakness (n = 1), altered mental status (n = 1), hypophosphatemia (n = 1)/2 patients had mild irAEs, including a grade 2 hepatic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 0                                                                                                                                                                                                                                                                                                                                                                 0                                  4                                                                                                                                                     Grade 2 colitis: n = 1(20%), budesonide, dosage NR, and continued pembrolizumab\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Grade 2 hepatitis: n = 1(20%), high dose of prednisone, and discontinued pembrolizumab.

  Pazopanib                                                                                                    40             18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0                                  18                                                                                                                                                    

                          Pembrolizumab                Qiao et al.         About 15 months                     1              NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NR                                                                                                                                                                                                                                                                                                                                                                NR                                 0                                                                                                                                                     NR

                          Nivolumab                    Amin et al.         Pazo: 13.9 months\                  20             Fatigue (n = 3), diarrhea (n = 4), hypertension (n = 2), increased alt (n = 4), increased AST (n = 4), hypothyroidism (n = 1), arthralgia (n = 1)/endocrine (n = 2), gastrointestinal (n = 4), hepatic (n = 4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         0                                                                                                                                                                                                                                                                                                                                                                 14                                 Discontinuation: n = 5 (25%)\                                                                                                                         
                                                                           Nivo: 15.1 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Systemic corticosteroid: n = 12(60%), including prednisone \[n = 11 (55%)\], dexamethasone \[n = 2 (10%)\], and methylprednisolone \[n = 2 (10%)\].   

                                                       Paoluzzi et al.     Nivo: 8 cycles (16 weeks)           18             AST elevation (n = 1), ALT elevation (n = 3), alkaline bilirubin elevation (n = 2), pneumonitis (n = 1), colitis (n = 1).\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Bilirubin elevation (n = 1), AST elevation (n = 1)                                                                                                                                                                                                                                                                                                                0                                  4                                                                                                                                                     Discontinuation of both nivolumab and pazopanib: n = 4 (22%), among which, two patients restarted on treatment with both drugs, while one patient restart pazopanib only\
                                                                                                                              The total number of patient who suffered grade 3/4 trAEs was 4.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  High-dose steroids (prednisone 1 mg/kg/daily), with a slow taper over about 2 months: n = 3\
                                                                                                                              The frequencies of trAEs significantly increased with addition of pazopanib \[4 (22%) of 18 vs. 0 (0%) of 10\].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   One patients needed intubation.

                                                       Yu-Li Su et al.     4 months                            1              NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NR                                                                                                                                                                                                                                                                                                                                                                NR                                 0                                                                                                                                                     NR

  Sorafenib                                                                                                    7              0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      0                                                                                                                                                                                                                                                                                                                                                                 0                                                                                                                                                                                        

                          Pembrolizumab                Chen et al.         NR                                  1              NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NR                                                                                                                                                                                                                                                                                                                                                                NR                                 0                                                                                                                                                     To avoid tumor rupture, the schedule of pembrolizumab was changed to every 4 weeks starting in cycle three.

                          Nivolumab                    Feng et al.         Nivo: 7.1 cycles                    6              NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NR                                                                                                                                                                                                                                                                                                                                                                NR                                 0                                                                                                                                                     NR

  Sunitinib                                                                                                    34             27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0                                  27                                                                                                                                                    

                          Nivolumab                    Amin et al.         Suni: 28 months\                    33             Fatigue (n = 3), diarrhea (n = 3), nausea (n = 1), hypertension (n = 6), decreased appetite (n = 1), increased alt (n = 6), increased AST (n = 3), blood creatinine increased (n = 2), vomiting (n = 1)/skin (n = 2), gastrointestinal (n = 3), hepatic (n = 8), renal (n = 4), pulmonary (n = 1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      0                                                                                                                                                                                                                                                                                                                                                                 27                                 Discontinuation of both nivolumab and sunitinib: n = 13(39.4%)\                                                                                       
                                                                           Nivo: 45.1 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Systemic corticosteroid n = 13 (39.4%) (prednisone, dexamethasone, and methylprednisolone)                                                            

                                                       Mahmoud et al.      Suni: ≥11 months\                   1              NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NR                                                                                                                                                                                                                                                                                                                                                                0                                  0                                                                                                                                                     NR
                                                                           Nivo: ≥8 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

![**(A)** Included studies and patients; X-axis: n, number of included studies. Severe trAE evaluation of concurrent use of antiangiogenic mAbs **(B)** or TKIs **(C)** with each class of ICIs.](fphar-10-01173-g002){#f2}

Toxicity of Concurrent ICIs and Antiangiogenic mAbs (Bevacizumab and Ramucirumab) {#s3_2}
---------------------------------------------------------------------------------

### Anti-CTLA-4 (Ipilimumab) {#s3_2_1}

One prospective study ([@B36]) and one case series ([@B12]) were identified ([**Table 1**](#T1){ref-type="table"}), examining concurrent ipilimumab and bevacizumab in melanoma and glioblastoma, respectively. The median dose of bevacizumab ranged from 7.5 to 15 mg/kg, and the dose of ipilimumab was 3 or 10 mg/kg every 3 weeks. Hodi et al. reported a total of 32 grade 3/4 trAEs in 13 patients, including one grade 4 hepatic and two grade 4 proteinuria. Among them, grade 3/4 trAEs in four cohorts were 5 (15.6%), 11 (34.4%), 6 (18.8%), and 10 (31.3%), respectively ([**Table 3**](#T3){ref-type="table"}). It seemed that the incidence of severe trAEs tended to elevate with the increase dose of bevacizumab. But it did not seem to increase the incidence of dermatologic or gastrointestinal side effects such as colitis, which were more concerning for ipilimumab treatment ([@B36]). In addition, one case series reporting the combination regimen in glioblastoma observed seven grade 3 trAEs. However, all immune-related toxicities were manageable with corticosteroids, without diagnosing of endocrinopathies ([@B12]).

In summary, limited available data indicated potential toxicity of concurrent ipilimumab and bevacizumab. But at least, it did not seem to increase the incidence of some special interest irAEs. Data on the combination of ipilimumab and ramucirumab is lacking.

### Anti-PD-1 (Pembrolizumab and Nivolumab) {#s3_2_2}

For pembrolizumab, there were two phase 1 trials ([@B4]; [@B30]), two retrospective studies ([@B8]; [@B46]), and one case report ([@B88]). Among them, four were concerning combined with bevacizumab, and one was with ramolumab. In the study of Gadgeel et al. where 24 patients with advanced non-squamous NSCLC received concurrent pembrolizumab, bevacizumab, and chemotherapy, grade 3 trAEs occurred in 10 (42%) patients, which was similar to patients treated without bevacizumab \[10 (40%)\]. But the grade 3 irAEs (colitis, pneumonitis, and pancreatitis) and infusion reaction occurred in five (20.8%) and one (4%) patients treated with or without addition of bevacizumab ([**Table 3**](#T3){ref-type="table"}) ([@B30]). In the two retrospective studies, concomitant use of pembrolizumab and bevacizumab in recurrent central nervous system (CNS) tumor was well tolerated, with no significant toxicity ([@B8]; [@B46]). The only one case report by [@B88] observed no grade 3--5 trAEs in one patient with urothelial carcinoma (UC) receiving such a concurrent regimen ([@B88]). There was only one phase 1 trial, treating a total of 26 patients with concurrent pembrolizumab and ramucirumab for advanced or metastatic biliary tract cancer (BTC). A total of seven (27%) grade 3 trAEs of 26 patients were observed, with hypertension accounting for 71% ([**Table 3**](#T3){ref-type="table"}) ([@B4]).

As for nivolumab, two retrospective studies on recurrent high-grade gliomas (HGGs) ([@B46]; [@B54]), one phase 1b trial and one case report on non-squamous NSCLC ([@B44]; [@B77]) and one prospective trial on platinum resistant ovarian cancer ([@B61]) were identified ([**Table 1**](#T1){ref-type="table"}). In the two retrospective studies (n = 71 patients), a total of four (5.6%) patients experienced grade 3/4 trAEs, among which there were three cases of irAEs including colitis and pneumonitis ([**Table 3**](#T3){ref-type="table"}) ([@B46]; [@B54]). The phase 1b trial of concurrent nivolumab, bevacizumab, and chemotherapy for NSCLC patients observed a total of 14 grade 3/4 trAEs of 6 patients. However, all of them were hematological AEs, and no grade 3/4 irAEs were reported ([@B44]). The prospective trial by Normann et al. observed a grade 3 hepatitis, and one death (grade 5) of intestinal perforation which was believed to be caused by bevacizumab in recurrent ovarian cancer patients. They also found that there was a tendency to increase toxicity when using concomitant nivolumab and bevacizumab \[2 (40%) of 5 vs. 1 (11%) of 9\] ([**Table 3**](#T3){ref-type="table"}) ([@B61]). Besides, Shirali, et al. reported one event of grade 3 acute interstitial nephritis in a progressive NSCLC patient treated with concurrent nivolumab and bevacizumab ([@B77]).

In summary, although the available data was limited, it suggested that concurrent use of pembrolizumab/nivolumab and bevacizumab is relatively safe. The data on the combination of pembrolizumab/nivolumab and ramucirumab is insufficient for conclusions.

### Anti-PD-L1 (Atezolizumab) {#s3_2_3}

Bevacizumab was combined with atezolizumab in four prospective studies ([@B83]; [@B57]; [@B72]; [@B74]). Three were associated with unresectable or metastatic RCC, and one was about chemotherapy-naïve metastatic non-squamous NSCLC ([**Table 1**](#T1){ref-type="table"}). The median follow-up ranged from 15 to 20.7 months. In total, 468 severe trAEs (≥grade 3), including 17 treatment-related deaths (grade 5), were reported of 956 patients ([**Table 3**](#T3){ref-type="table"}). But our search did not find studies on concurrent atezolizumab and ramucirumab.

In patients with RCC, grade 3/4 trAEs were observed in 228 (40.6%) of 562 patients, and also 6 (1.1%) grade 5 trAEs were reported, consisting of 2 intracranial hemorrhage, 1 cerebral infarction, 1 adrenal insufficiency, 1 multiple organ dysfunction syndrome, and 1 sepsis ([**Table 3**](#T3){ref-type="table"}). An early clinical trial reported six grade 3/4 trAEs, but none of them were deemed related to atezolizumab ([@B83]). McDermott et al found that concurrent atezolizumab and bevacizumab led to a significantly increase of the incidence of grade 3--5 trAEs (40 *vs*. 17%), but the incidence of irAEs was similar (5 *vs*. 3%) ([@B57]). The phase 3 trial of Rini et al. observed that patients given atezolizumab plus bevacizumab had lower frequency of grade 3/4 trAEs than that of sunitinib (40 *vs*. 54%) ([**Table 3**](#T3){ref-type="table"}) ([@B74]). Regarding NSCLC, the only one phase 3 trial suggested that when adding atezolizumab to bevacizumab and chemotherapy, grade 3/4 trAEs and treatment-related death (grade 5) slightly elevated, while the increase degree was higher when adding bevacizumab to atezolizumab and chemotherapy. However, the addition of bevacizumab did not significantly increase the incidence of irAEs (12.5 *vs*. 9.5%) ([**Table 3**](#T3){ref-type="table"}) ([@B72]). Information about the AEs was from an article that reporting the same trial ([@B78]).

In summary, concurrent atezolizumab and bevacizumab might increase trAEs, but not irAEs. In addition, no unexpected patterns of toxicity emerged in the combination therapy. Data about the combination of atezolizumab and ramucirumab is not available.

Toxicity of Concurrent ICIs and Antiangiogenic TKIs (Apatinib, Axitinib, Cabozantinib, Cediranib, Lenvatinib, Pazopanib, Sorafenib, Sunitinib) {#s3_3}
----------------------------------------------------------------------------------------------------------------------------------------------

### Anti-PD-1 (Pembrolizumab, Nivolumab) {#s3_3_1}

The concomitant use of pembrolizumab and antiangiogenic TKIs was examined in seven studies ([@B16]; [@B5]; [@B41]; [@B70]; [@B53]; [@B73]; [@B85]), which were highly diverse in research and tumor types ([**Table 2**](#T2){ref-type="table"}). In a phase 1b study, where a total of 52 RCC patients received concurrent pembrolizumab and axitinib, grade 3/4 trAEs were observed in 34 patients. The most common trAEs, such as diarrhea (8%) and elevations in liver-enzyme levels (8%), seemed to be largely related to axitinib rather than a true irAE predominantly due to pembrolizumab ([@B5]). Similarly, the phase 3 trial by Rini et al. reported 270 (51%) grade 3 or higher toxicities of 429 patients ([**Table 3**](#T3){ref-type="table"}), which were as expected on the basis of the known profiles of each drug. Although there were four (0.9%) patients died from trAEs, none of them related to hepatic adverse that might be more challenging due to the overlapping toxicities of axitinib and pembrolizumab. Moreover, combined group had fewer treatment-related death than sunitinib \[4 (0.9%) *vs*. 7 (1.6%)\] ([@B73]). We also found a phase 2 trial of this combined regimen for soft-part sarcoma. A total of 16 grade 3/4 trAEs occurred in 33 patients, and grade 3/4 irAEs in 5 (15%) patients ([@B85]). Two studies examining concurrent pembrolizumab and lenvatinib were identified. In a phase 2 trial of metastatic endometrial cancer, Makker et al. observed 36 (68%) patients with grade 3 trAEs and a grade 5 intracranial hemorrhage. Among them, there were 30 irAEs in total, but the grade was not described in detail ([**Table 3**](#T3){ref-type="table"}) ([@B53]). One retrospective study for progressive anaplastic thyroid carcinoma (ATC) reported four grade 3 trAEs of five patients and some mild irAEs (such as grade 2 hepatitis) ([@B41]). Two case reports about concurrent pembrolizumab and pazopanib for primary hepatic angiosarcoma (PHA) ([@B70]) and pembrolizumab plus sorafenib for HCC ([@B16]) did not observe any significant toxicity.

Regarding nivolumab, there were three studies examining concurrent nivolumab and pazopanib ([@B64]; [@B2]; [@B90]), two for combining with sunitinib ([@B52]; [@B2]), and one for combining with apatinib ([@B91]), cabozantinib ([@B7]) or sorafenib ([@B26]), respectively ([**Table 2**](#T2){ref-type="table"}). Zhao et al. observed grade 3 elevated aminotransferases in a patient with advanced liver carcinosarcoma treated with nivolumab plus apatinib ([@B91]), while Bhat et al. did not observe severe trAEs in a patients treated with nivolumab plus cabozantinib ([@B7]). In the phase 1 trial of Amin et al. 27 (81.8%) and 14 (70.0%) patients in arms nivolumab plus sunitinib and nivolumab plus pazopanib, respectively, experienced grade 3/4 trAEs, and 18 (55%) and 10 (50%) patients, respectively, experienced grade 3/4 irAEs ([**Table 3**](#T3){ref-type="table"}). The rate of arm nivolumab plus pazopanib was higher than that of arm nivolumab or pazopanib monotherapy in previous reports ([@B2]. Paoluzzi et al. reported 10 grade 3/4 trAEs in 4 (22.2%) patients receiving concomitant nivolumab and pazopanib, but no grade 3/4 trAEs occurred in nivolumab monotherapy group ([@B64]). Yu-Li Su et al. observed no toxicity after treatment of concurrent nivolumab and pazopanib in a patient with metastatic RCC ([@B90]). Feng et al. analyzed nivolumab combined with sorafenib for advanced HCC in six patients and observed no severe toxicity ([@B26]), while Mahmoud et al. did not observe severe trAEs in a patient treated with nivolumab plus sunitinib ([@B52]).

In summary, data on the toxicity of concurrent anti-PD-1 antibody and TKIs was conflicting. Some severe trAEs of the combination seemed to be largely related to TKIs, rather than a true irAE predominantly due to anti-PD-1 monotherapy. However, most studies were early phase clinical trials or case report, not randomized controlled studies with a large population, so the data is insufficient for conclusions.

### Anti-PD-L1 (Avelumab, Durvalumab) {#s3_3_2}

Two prospective studies ([@B18]; [@B60]) evaluated concurrent use of avelumab and axitinib on advanced RCC. A total of 282 (57.7%) in 489 patients experienced grade 3--5 trAEs, of which the most frequent were diarrhea, hypertension, fatigue, palmar--plantar erythrodysesthesia syndrome, and changes of liver enzymes ([**Table 3**](#T3){ref-type="table"}). In addition, in the phase 1b trial of Choueiri et al. where 55 patients received avelumab plus axitinib, one patient developed a fatal treatment-related autoimmune myocarditis ([@B18]). In the prospective phase 3 trial of Motzer et al., three (0.7%) treatment-related deaths were attributed to sudden death, myocarditis, and necrotizing pancreatitis, respectively ([@B60]) ([**Table 3**](#T3){ref-type="table"}). However, the trAEs observed with combination therapy were generally consistent with the known safety profiles of monotherapy. No new toxicities were reported.

Currently, only one phase 1 trial, treating a total of 14 patients with concurrent durvalumab and cediranib for several recurrent or metastatic solid tumors, was found ([**Table 2**](#T2){ref-type="table"}). Lee et al. observed 19 grade 3/4 trAEs occurred in 7 patients. In durvalumab plus intermittent cediranib, the severe AEs were only one grade 3 fatigue and one grade 4 hypertension. In contrast, daily cediranib with durvalumab was not well tolerated ([**Table 3**](#T3){ref-type="table"}) ([@B49]).

In summary, the very small number of patients treated with avelumab plus axitinib or durvalumab plus cediranib and lack of compared monotherapy group make it difficult to draw conclusions about their safety.

Management of irAEs {#s3_4}
-------------------

In the included literatures, holding the ICI treatment was the first thing for managing grade 3/4 irAEs, and most of studies did not reduce the dose of ICIs, with an exception for one. In the case, a patient with HCC had a low-grade fever relating to remarkable tumor necrosis. Thus, to avoid tumor rupture, the schedule of pembrolizumab was changed to every 4 weeks ([@B16]). Besides, high-dose corticosteroids (including prednisone, methylprednisolone, and dexamethasone) were the first line for treating irAEs, and often effective in alleviating symptoms ([**Table 3**](#T3){ref-type="table"}). As some severe trAEs that were largely related to the addition of antiangiogenic agents, reducing or holding dose, as well as adjusting administration frequency of the antiangiogenic drugs, were the other common ways to deal with treatment-related toxicity ([**Table 3**](#T3){ref-type="table"}) ([@B12]; [@B49]; [@B2]; [@B5]; [@B18]; [@B60]; [@B73]; [@B85]). In addition, the rest of trAEs were managed with symptomatic treatment such as drugs or surgery ([**Table 3**](#T3){ref-type="table"}).

Discussion {#s4}
==========

In this review, we demonstrated the risk of added toxicity of concurrent ICIs and antiangiogenic agents, but there are not abundant of data from multi-institutional randomized controlled trials (RCTs) to draw an exact conclusion. From the available data, bevacizumab and axitinib were the most commonly used antiangiogenic agents for concomitant treatment. For other antiangiogenic drugs, available safety information is primarily based on small, retrospective single institution experiences, and even case report. In terms of tumor types, the three most numerous studies on concurrent ICIs and antiangiogenic agents were RCC, non-squamous NSCLC, and CNS tumors (including glioblastoma) ([**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}). However, the combination of the two types of therapies is indeed a research hotspot at present, with a huge amount of ongoing trials ([**Table 4**](#T4){ref-type="table"}).

###### 

Parts of ongoing phase 2/3 clinical trials of ICIs combined with antiangiogenic agents.

  ICIs                        Antiangiogenic agents      Primary tumor                                                                                                                            Status and end points                                                                                                                                                          CliniclTrials.gov identifier
  --------------------------- -------------------------- ---------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------
  Nivolumab                   Bevacizumab                Glioblastoma                                                                                                                             Phase 2: recruiting (OS, ORR, DOR, and PFS)                                                                                                                                    NCT03452579
                              Ramucirumab                Mesothelioma, malignant                                                                                                                  Phase 2: recruiting (ORR, AEa, PFS, and OS)                                                                                                                                    NCT03502746
                              Axitinib                   Renal cell carcinoma                                                                                                                     Phase 2: recruiting (AEs, ORR, DOR, PFS, OS, PD-L1 expression, and tumor infiltrating lymphocyte assessments, pharmacodynamic effect of study treatment including cytokines)   NCT03172754
                              Cabozantinib               Renal cell carcinoma                                                                                                                     Phase 3: recruiting (PFS, OS, ORR, AEs, SAEs)                                                                                                                                  NCT03141177
                              Lenvatinib                 Advanced hepatocellular carcinoma                                                                                                        Phase 2: recruiting (ORR, AEs, SAEs, TTP, PFS, OS, and translational research)                                                                                                 NCT03841201
                              Regorafenib                Advanced and metastatic solid tumor                                                                                                      Phase 1/2: recruiting (RD, MTD, ORR, PFS, DCR, OS, and AEs)                                                                                                                    NCT03406871
                              Sunitinib                  Soft tissue sarcoma, bone sarcoma                                                                                                        Phase 1/2: recruiting (PFSR, OS, ORR, immune response, tumor response, AEs, and clinical outcome)                                                                              NCT03277924
                              Sorafenib                  Hepatocellular carcinoma                                                                                                                 Phase: recruiting (MTD, ORR, DOR, AEs, irAEs, OS, and PFS)                                                                                                                     NCT03439891
  (Nivolumab + ipilimumab)    Cabozantinib               Genitourinary tumors                                                                                                                     Phase 2: recruiting (ORR, DOR, PFS, OS, CBR, AEs, and effects of treatment in patients with bone-only disease)                                                                 NCT03866382
                              Nintedanib                 Non-small-cell lung cancer metastatic                                                                                                    Phase 1/2: recruiting (MTD, ORR, DCR, OS, and PFS)                                                                                                                             NCT03377023
  SHR 1210 (anti-PD-1 mAb)    Apatinib                   Gastric cancer and HCC                                                                                                                   Phase 1/2: recruiting (OSR, tumor control rate, DCR, DOR, and AEs)                                                                                                             NCT02942329
  Pembrolizumab               Bevacizumab                Colorectal cancer, metastatic cancer                                                                                                     Phase 2: recruiting (ORR, PFS, OS, and AEs)                                                                                                                                    NCT03475004
                              Ramucirumab                Head and neck squamous cell carcinoma                                                                                                    Phase 1/2: recruiting (RP2D, ORR, AEs, DOR, PFS, OS, and changes in quality of life)                                                                                           NCT03650764
                              Apatinib                   Advanced urothelial carcinoma, advanced MSI-H or dMMR solid tumors, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma   Phase 1/2: recruiting (DLTs, ORR, and PFS)                                                                                                                                     NCT03407976
  (Pembrolizumab+ D-CIK)      Axitinib                   Renal cancer metastatic                                                                                                                  Phase 2: recruiting (ORR, PFS, OS, DOR, the quality of life, and AEs)                                                                                                          NCT03736330
                              Anlotinib                  Advanced solid tumor                                                                                                                     Phase 2/3: recruiting (PFS, ORR, DCR, and OS)                                                                                                                                  NCT03975036
                              Cabozantinib               Advanced metastatic melanoma                                                                                                             Phase 1/2: not yet recruiting (DLTs, ORR, DCR, PFS, and OS)                                                                                                                    NCT03957551
                              Lenvatinib                 Thyroid gland carcinoma                                                                                                                  Phase 2: recruiting (CR, AEs, PFS, OS, AEs, and biomarker levels)                                                                                                              NCT02973997
                              Regorafenib                Metastatic colorectal cancer                                                                                                             Phase 1/2: not yet recruiting (DLTs, PFS, and OS)                                                                                                                              NCT03657641
                              Sunitinib                  Thymic carcinoma                                                                                                                         Phase 2: recruiting (ORR, AEs, OS, PFS, and PD-L1 expression)                                                                                                                  NCT03463460
                              Sorafenib                  Hepatocellular carcinoma                                                                                                                 Phase 1b/2: recruiting (ORR, OS. TTP, change in functional activity of effector T cells, and levels of immunosuppressive cell PFS)                                             NCT03211416
  Atezolizumab (MPDL3280A)    Bevacizumab+chemotherapy   Ovarian cancer                                                                                                                           Phase 3: recruiting (efficacy, TSST, OS, and AEs)                                                                                                                              NCT02891824
                              Ramucirumab                Non-small-cell lung cancer                                                                                                               Phase 2: recruiting (OS, CBR, and irAEs)                                                                                                                                       NCT03689855
                              Cabozantinib               Hepatocellular carcinoma                                                                                                                 Phase 3: recruiting (PFS and OS)                                                                                                                                               NCT03755791
  Avelumab                    Ramucirumab++paclitaxel    Gastroesophageal junction Adenocarcinoma/adenocarcinoma of the stomach                                                                   Phase 2: recruiting (OSR, OS, PFS, PFSR, DOR, ORR et al.)                                                                                                                      NCT03966118
                              Axitinib                   Non-small-cell lung cancer; urothelial cancer                                                                                            Phase 2: recruiting (ORR, TTR, tumor tissue biomarker status, ADA, DOR, PFS, Cmax of axitinib or avelumab, OS et al.)                                                          NCT03472560
                              Regorafenib                Metastatic solid tumors                                                                                                                  Phase 1/2: recruiting (pharmacokinetics, RP2D, antitumor activity, MTD, DLT, toxicity, ORR, PFS, and blood biomarkers et al.)                                                  NCT03475953
  Durvalumab                  Bevacizumab                Hepatocellular carcinoma                                                                                                                 Phase 3: recruiting (RFS, OS, RFS24 h/36 h, TTR)                                                                                                                               NCT03847428
                              Pazopanib                  Sarcoma                                                                                                                                  Phase 2: not yet recruiting (progression free rate: antitumor efficacy)                                                                                                        NCT03798106
  MEDI4736 (anti-PD-L1 mAb)   Cediranib                  Colorectal neoplasms; breast neoplasms                                                                                                   Phase 1/2: recruiting (RP2D and ORR)                                                                                                                                           NCT02484404

Usually, immune checkpoint blockade treatment is associated with multitude and atypical types of tumor responses and has specific toxicity profiles which are termed irAEs ([@B87]; [@B31]). In general, within the first 3--4 months of treatment, 80% patients may experience irAEs ([@B17]; [@B58]). Because of the different functions of CTLA-4 and PD-1/PD-L1, the types and frequency of irAEs related to various checkpoint inhibitors were different ([@B58]). Anti-CTLA-4 antibodies mostly affect the skin (44%) and the gastrointestinal tract (35%), whereas the endocrine (6%) and hepatic (5%) systems are rarely affected ([@B9]; [@B19]; [@B24]). The side effects of anti-PD-1/PD-L1 antibodies are less frequent and less severe than those of anti-CTLA-4 antibodies ([@B13]; [@B69]). The main AEs of PD-1 and PD-L1 blocking agents are pneumonia, myalgia, hypothyroidism, arthralgia, and vitiligo ([@B9]; [@B19]). In this review, the frequencies, types, and severities of irAEs that mentioned in most of studies were consistent with previous data for ICI treatment alone, and trAEs of combination regimen were largely consistent with the known safety profiles of each monotherapy. Besides, the data of included literatures suggested that some severe trAEs of the concurrent treatment were largely related to the addition of antiangiogenic agents, rather than a true irAEs caused by ICIs ([@B36]; [@B5]; [@B78]; [@B72]). In addition, frequency of severe trAEs in ICI plus TKI groups was a little higher than that of ICIs plus mAbs groups, which may be explained by the multiple targets of TKIs. The toxicities consist of not only AEs related to the blockade of VEGR/VEGFR pathway but also AEs caused by additional targets inhibition ([@B15]; [@B71]). For example, sunitinib (targeting VEGFR-1/2, PDGFR-α/β, Flt-3, and c-kit) is known to cause both neutropenia and thrombocytopenia as a result of VEGF inhibition and simultaneous inhibition of c-kit ([@B21]; [@B15]). Similarly, anemia and decrease of both platelet and neutrophil counts were observed in an included study of concurrent avelumab and axitinib (targeting VEGFR-1--3, PDGFR, and c-kit) ([@B55]; [@B73]). Therefore, the selection of optimal components for combination therapy is worthy of further research.

In general, most irAEs are mild and manageable, although a few patients treated with ICIs develop severe irAEs (grade 3/4), even immune-related death (grade 5). Recommendations on the management of irAEs have been published as the guidelines in Europe and the United States ([@B69]; [@B10]; [@B33]). Firstly, successful management of irAEs requires standardize grading based on the common terminology criteria for adverse events (CTCAE 4.0) grading. As for intervention, patients with grade 1 irAEs can continue immunotherapy, except for some neurologic, hematologic, and cardiac toxicities. Holding ICI treatment should be considered for most grade 2 irAEs until symptoms and/or laboratory values reduce to grade 1 or less and then treat them with locally or orally small doses of corticosteroids (0.5--1 mg/kg/d of prednisone or equivalent). For grade 3 irAEs, discontinuation of the ICI therapy and giving moderate to high-dose corticosteroids (prednisone 1--2 mg/kg/d or methylprednisolone i.v. 1 to 2 mg/kg/d) are recommended. Resuming treatment should be caution depending on the risk/benefit ratio. Regarding to life-threatening events (grade 4), hospitalization and high-dose corticosteroids (methylprednisolone i.v. 1-2 mg/kg/d) or other immunosuppressive measures (infliximab 5 mg/kg) are necessary. And ICI treatment should be permanently discontinued ([@B13]; [@B69]; [@B10]). In the included studies, most of immune-related toxicities of the concurrent treatment were managed *via* holding ICI treatment and adding corticosteroids. Reducing dose or adjusting the administration frequency of the antiangiogenic drugs was also used to alleviate some symptoms of trAEs ([**Table 3**](#T3){ref-type="table"}). However, the information concerning the new advances and management of irAEs are limited.

Recently, irAEs were considered as therapy-induced loss of tolerance, similar to autoimmune disorders ([@B9]; [@B68]; [@B67]). Thus, the known risk factors for autoimmunity may also predict the risk of irAEs. [@B38] searched for susceptible loci associated with various autoimmune diseases and pooled them in groups most likely to be associated with ICIs-induced irAEs ([@B38]), which may help to screening out patients with pre-existing subclinical autoimmune disorders or susceptibility to autoimmune diseases and guide physicians in a more refined and personal manner. Besides, depending on the degree of similarity between irAEs and autoimmune disorders, we can find reference in therapies developed for autoimmunity to manage irAEs ([@B67]). For example, anti-TNF-α antibodies are usually used to treat steroid-refractory inflammatory bowel disease and could also alleviate ICIs-induced colitis ([@B22]). Also, experts in autoimmune disorders should be involved in the care of cancer patients receiving ICIs. In addition, studies have found that gut microbiome is not only associated with the efficacy of immunotherapy but also with some specific irAEs, such as colitis ([@B63]). Thus, the ability to predict which patient has a high risk of developing ICI-induced colitis is very valuable to clinicians who have to weigh the potential risks and benefits of ICI therapy. Regarding to the combination of ICIs and antiangiogenic agents, the problem also includes the dose, optimal duration of treatment, and sequencing of each therapy. As is well known, anti-VEGF therapies have the window of normalization ([@B86]; [@B40]), with the dose and duration time of antiangiogenic agents being the key modulating factors ([@B40]; [@B14]). High dose or long duration time of antiangiogenic therapy are associated with aggressive ablation of the vasculature, leading to higher degree of hypoxia and immunosuppression ([@B40]; [@B1]). Thus, reducing the dose of antiangiogenic agents has been taken into account in the design of some clinical trials with the combination of ICIs ([@B27]). Besides, as vascular normalization can enhance delivery and distribution of ICIs in the tumor tissues, the low dose of ICIs may help to reduce the incidence and severity of irAEs ([@B27]). In addition, identification of predictive or prognostic markers is also expected to help screening suitable patients in order to prevent unnecessary side effects of combination therapy. Previous study found that expression level of PD-L1 was a predictive marker of the response to immunotherapy and also a negative prognostic marker in RCC patients receiving VEGF-targeted therapy ([@B76]). Angiopoietin 2 (ANG2), a vessel-destabilizing ligand of TIE2 and a critical regulator of blood vessel maturation, is a potential biomarker of resistance to anti-VEGF therapy ([@B6]; [@B43]; [@B47]). At the same time, evidence showing high serum level of ANG2 was inversely correlated with treatment response and prognosis of ICI treatment in metastatic melanoma patients ([@B20]). Therefore, it is not so sensible to provide such a combined strategy for this kind of patients.

The current review has limitations that the number of available studies, especially RCTs, is insufficient. Even for some drugs, the data is lacking. These may partly due to the fact that many studies assessing the combination treatment of ICIs and antiangiogenic agents are still ongoing for this emerging area of research. Besides, the information about the new advances and management of irAEs in the included studies are limited. In addition, the review mainly focuses on three well known immune checkpoints, CTLA-4, PD-1, and PD-L1. However, identification of better biomarkers or therapeutic agents aimed at improving the clinical response in refractory patients and reducing irAEs is also necessary, which has led to the development of "next-generation" ICIs, such as T cell immunoglobulin mucin 3 (TIM-3), lymphocyte activation gene 3 (LAG-3), T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), indoleamine-2,3-dioxygenase 1 (IDO1), and so on ([@B56]). Hundreds of registered past and ongoing clinical trials investigate the mechanism and efficiency of "next-generation" ICIs either as monotherapy or combining with other ICIs ([@B56]; [@B81]). Therefore, updated information is still required in the future.

Conclusion {#s5}
==========

In summary, concurrent ICIs and antiangiogenic agents show potential treatment-related toxicity. Further research is required to compare the efficacy and safety of the combined regimen and the corresponding monotherapy. It is also necessary to explore dose, duration, and sequencing schedule of drugs, as well as identify predictive or prognostic biomarkers.
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